Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 1/20 | 0.53 |
| ▸ | CMA1 | P23946 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5966500 | 0.87 | HDAC1 (0.63) | PARP1PARP3HDAC6HDAC1 | |
| SCHEMBL4145476 | 0.87 | HDAC1 (0.63) | PARP1PARP3HDAC6HDAC1 | |
| SCHEMBL4145473 | 0.87 | HDAC1 (0.63) | PARP1PARP3HDAC6HDAC1 | |
| SCHEMBL13673884 | 0.86 | ACE (0.67) | CTSGCMA1ITGB3ITGA2BACE | |
| SCHEMBL4152421 | 0.86 | ACE (0.67) | CTSGCMA1ITGB3ITGA2BACE | |
| SCHEMBL8257179 | 0.85 | ITGB3 (0.48) | CTSGCMA1ITGB3ITGA2BACE | |
| SCHEMBL23169896 | 0.84 | ALDH1A1 (0.62) | CTSGCMA1ITGB3ITGA2BACE | |
| SCHEMBL5458748 | 0.83 | ITGB3 (0.65) | CTSGCMA1ITGB3ITGA2BACE | |
| SCHEMBL4153095 | 0.83 | ITGB3 (0.65) | CTSGCMA1ITGB3ITGA2BACE | |
| SCHEMBL4153101 | 0.83 | ITGB3 (0.65) | CTSGCMA1ITGB3ITGA2BACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185060-A1 | Boronic acid thrombin inhibitors | TRIGEN LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185060-A1 | Boronic acid thrombin inhibitors | F2, ECE1, BCAT1 | CTSG 1511/4885CMA1 260/4885ITGB3 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.